121 related articles for article (PubMed ID: 18220757)
1. Glycosylation of HIV-1 gp120 V3 loop: towards the rational design of a synthetic carbohydrate vaccine.
Sirois S; Touaibia M; Chou KC; Roy R
Curr Med Chem; 2007; 14(30):3232-42. PubMed ID: 18220757
[TBL] [Abstract][Full Text] [Related]
2. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
3. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.
Yang Q; Li C; Wei Y; Huang W; Wang LX
Bioconjug Chem; 2010 May; 21(5):875-83. PubMed ID: 20369886
[TBL] [Abstract][Full Text] [Related]
4. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
5. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.
Chaillon A; Braibant M; Moreau T; Thenin S; Moreau A; Autran B; Barin F
J Virol; 2011 Apr; 85(7):3642-8. PubMed ID: 21248038
[TBL] [Abstract][Full Text] [Related]
6. Negatively charged glyconanoparticles modulate and stabilize the secondary structures of a gp120 V3 loop peptide: toward fully synthetic HIV vaccine candidates.
Gianvincenzo PD; Calvo J; Perez S; Álvarez A; Bedoya LM; Alcamí J; Penadés S
Bioconjug Chem; 2015 Apr; 26(4):755-65. PubMed ID: 25734507
[TBL] [Abstract][Full Text] [Related]
7. Recent strategies targeting HIV glycans in vaccine design.
Horiya S; MacPherson IS; Krauss IJ
Nat Chem Biol; 2014 Dec; 10(12):990-9. PubMed ID: 25393493
[TBL] [Abstract][Full Text] [Related]
8. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135.
Huang X; Barchi JJ; Lung FD; Roller PP; Nara PL; Muschik J; Garrity RR
Biochemistry; 1997 Sep; 36(36):10846-56. PubMed ID: 9312273
[TBL] [Abstract][Full Text] [Related]
10. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.
Astronomo RD; Lee HK; Scanlan CN; Pantophlet R; Huang CY; Wilson IA; Blixt O; Dwek RA; Wong CH; Burton DR
J Virol; 2008 Jul; 82(13):6359-68. PubMed ID: 18434393
[TBL] [Abstract][Full Text] [Related]
11. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
Yu T; Bai Y; Dierich MP; Chen YH
Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
[TBL] [Abstract][Full Text] [Related]
12. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
13. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
Qi Y; Jo S; Im W
Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
[TBL] [Abstract][Full Text] [Related]
14. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
15. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.
Keller PM; Arnold BA; Shaw AR; Tolman RL; Van Middlesworth F; Bondy S; Rusiecki VK; Koenig S; Zolla-Pazner S; Conard P
Virology; 1993 Apr; 193(2):709-16. PubMed ID: 7681612
[TBL] [Abstract][Full Text] [Related]
16. Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen.
Liu CC; Zhai C; Zheng XJ; Ye XS
ACS Chem Biol; 2016 Jun; 11(6):1702-9. PubMed ID: 27088577
[TBL] [Abstract][Full Text] [Related]
17. Bioorganic approaches towards HIV vaccine design.
Wang LX
Curr Pharm Des; 2003; 9(22):1771-87. PubMed ID: 12871196
[TBL] [Abstract][Full Text] [Related]
18. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
19. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
Zolla-Pazner S; Cohen SS; Krachmarov C; Wang S; Pinter A; Lu S
Virology; 2008 Mar; 372(2):233-46. PubMed ID: 18061228
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
Pantophlet R; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
